<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-B9PCIJ6P</identifier><date>2016</date><creator>Rožman, Samo</creator><relation>documents/doc/B/URN_NBN_SI_doc-B9PCIJ6P_001.pdf</relation><relation>documents/doc/B/URN_NBN_SI_doc-B9PCIJ6P_001.txt</relation><format format_type="type">article</format><format format_type="extent">Str. 113-118</format><identifier identifier_type="COBISSID_HOST">2552443</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-B9PCIJ6P</identifier><language>slv</language><publisher>Kancerološko združenje Slovenskega zdravniškega društva</publisher><publisher>Onkološki inštitut</publisher><source>Onkološki vikend</source><rights>BY-NC-ND</rights><subject language_type_id="slv">imunoterapija</subject><subject language_type_id="slv">onkologija</subject><subject language_type_id="slv">sistemsko zdravljenje</subject><subject language_type_id="slv">solidni tumorji</subject><title>Razvojni trendi v onkološki farmaciji</title></Record>